Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis.

Bickelhaupt S, Erbel C, Timke C, Wirkner U, Dadrich M, Flechsig P, Tietz A, Pföhler J, Gross W, Peschke P, Hoeltgen L, Katus HA, Gröne HJ, Nicolay NH, Saffrich R, Debus J, Sternlicht MD, Seeley TW, Lipson KE, Huber PE.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw339.

PMID:
28376190
2.

Intensity modulated radiation therapy (IMRT) for sinonasal tumors: a single center long-term clinical analysis.

Askoxylakis V, Hegenbarth P, Timke C, Saleh-Ebrahimi L, Debus J, Röder F, Huber PE.

Radiat Oncol. 2016 Feb 4;11:17. doi: 10.1186/s13014-016-0595-9.

3.

Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer.

Roeder F, Nicolay NH, Nguyen T, Saleh-Ebrahimi L, Askoxylakis V, Bostel T, Zwicker F, Debus J, Timke C, Huber PE.

Radiat Oncol. 2014 Aug 29;9:191. doi: 10.1186/1748-717X-9-191.

4.

Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.

Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, Klapproth K, Schäkel K, Garbi N, Jäger D, Weitz J, Schmitz-Winnenthal H, Hämmerling GJ, Beckhove P.

Cancer Cell. 2013 Nov 11;24(5):589-602. doi: 10.1016/j.ccr.2013.09.014. Epub 2013 Oct 24.

5.

Aggressive local treatment containing intraoperative radiation therapy (IORT) for patients with isolated local recurrences of pancreatic cancer: a retrospective analysis.

Roeder F, Timke C, Uhl M, Habl G, Hensley FW, Buechler MW, Krempien R, Huber PE, Debus J, Werner J.

BMC Cancer. 2012 Jul 18;12:295. doi: 10.1186/1471-2407-12-295.

6.

LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals.

Flechsig P, Dadrich M, Bickelhaupt S, Jenne J, Hauser K, Timke C, Peschke P, Hahn EW, Gröne HJ, Yingling J, Lahn M, Wirkner U, Huber PE.

Clin Cancer Res. 2012 Jul 1;18(13):3616-27. doi: 10.1158/1078-0432.CCR-11-2855. Epub 2012 Apr 30.

7.

Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5 × 5 Gy) and intraoperative radiation therapy (15 Gy) in patients with primarily resectable pancreatic cancer - NEOPANC.

Roeder F, Timke C, Saleh-Ebrahimi L, Schneider L, Hackert T, Hartwig W, Kopp-Schneider A, Hensley FW, Buechler MW, Debus J, Huber PE, Werner J.

BMC Cancer. 2012 Mar 23;12:112. doi: 10.1186/1471-2407-12-112.

8.

Differentiation potential of pancreatic fibroblastoid cells/stellate cells: effects of peroxisome proliferator-activated receptor gamma ligands.

Kruse ML, Hopf-Jensen S, Timke C, Agricola B, Sparmann G, Schmid A, Sipos B, Arlt A, Schäfer H.

Int J Cell Biol. 2011;2011:816791. doi: 10.1155/2011/816791. Epub 2011 Oct 4.

9.

Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.

Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U, Lahn M, Huber PE.

Cancer Res. 2011 Dec 1;71(23):7155-67. doi: 10.1158/0008-5472.CAN-11-1212. Epub 2011 Oct 17.

10.

A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer.

Reissfelder C, Timke C, Schmitz-Winnenthal H, Rahbari NN, Koch M, Klug F, Roeder F, Edler L, Debus J, Büchler MW, Beckhove P, Huber PE, Weitz J.

BMC Cancer. 2011 Sep 30;11:419. doi: 10.1186/1471-2407-11-419.

11.

Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

Zhang M, Herion TW, Timke C, Han N, Hauser K, Weber KJ, Peschke P, Wirkner U, Lahn M, Huber PE.

Neoplasia. 2011 Jun;13(6):537-49.

12.

Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancer.

Timke C, Winnenthal HS, Klug F, Roeder FF, Bonertz A, Reissfelder C, Rochet N, Koch M, Tjaden C, Buechler MW, Debus J, Werner J, Beckhove P, Weitz J, Huber PE.

BMC Cancer. 2011 Apr 13;11:134. doi: 10.1186/1471-2407-11-134.

13.

Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer.

Roeder F, Zwicker F, Saleh-Ebrahimi L, Timke C, Thieke C, Bischof M, Debus J, Huber PE.

Radiat Oncol. 2011 Mar 1;6:22. doi: 10.1186/1748-717X-6-22.

14.

Reirradiation with intensity-modulated radiotherapy in recurrent head and neck cancer.

Zwicker F, Roeder F, Hauswald H, Thieke C, Timke C, Schlegel W, Debus J, Münter MW, Huber PE.

Head Neck. 2011 Dec;33(12):1695-702. doi: 10.1002/hed.21663. Epub 2011 Jan 31.

PMID:
21284054
15.

IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer.

Zwicker F, Roeder F, Thieke C, Timke C, Münter MW, Huber PE, Debus J.

Strahlenther Onkol. 2011 Jan;187(1):32-8. doi: 10.1007/s00066-010-2149-7. Epub 2010 Dec 23.

PMID:
21234529
16.

Local setup errors in image-guided radiotherapy for head and neck cancer patients immobilized with a custom-made device.

Giske K, Stoiber EM, Schwarz M, Stoll A, Muenter MW, Timke C, Roeder F, Debus J, Huber PE, Thieke C, Bendl R.

Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):582-9. doi: 10.1016/j.ijrobp.2010.07.1980. Epub 2010 Oct 8.

PMID:
20934279
17.

Conflicting results of prenatal FISH with different probes for Down's Syndrome critical regions associated with mosaicism for a de novo del(21)(q22) characterised by molecular karyotyping: Case report.

Eckmann-Scholz C, Gesk S, Nagel I, Haake A, Bens S, Heidemann S, Kautza M, Timke C, Siebert R, Caliebe A.

Mol Cytogenet. 2010 Sep 5;3:16. doi: 10.1186/1755-8166-3-16.

18.

New multileaf collimator with a leaf width of 5 mm improves plan quality compared to 10 mm in step-and-shoot IMRT of HNC using integrated boost procedure.

Zwicker F, Hauswald H, Nill S, Rhein B, Thieke C, Roeder F, Timke C, Zabel-du Bois A, Debus J, Huber PE.

Strahlenther Onkol. 2010 Jun;186(6):334-43. doi: 10.1007/s00066-010-2103-8. Epub 2010 May 21.

PMID:
20495969
19.

Intensity modulated radiotherapy (IMRT) in benign giant cell tumors--a single institution case series and a short review of the literature.

Roeder F, Timke C, Zwicker F, Thieke C, Bischof M, Debus J, Huber PE.

Radiat Oncol. 2010 Feb 26;5:18. doi: 10.1186/1748-717X-5-18. Review.

20.

Correlation of patient-related factors and dose-volume histogram parameters with the onset of radiation pneumonitis in patients with small cell lung cancer.

Roeder F, Friedrich J, Timke C, Kappes J, Huber P, Krempien R, Debus J, Bischof M.

Strahlenther Onkol. 2010 Mar;186(3):149-56. doi: 10.1007/s00066-010-2018-4. Epub 2010 Feb 22.

PMID:
20165822
21.

Intraoperative electron radiotherapy for the management of aggressive fibromatosis.

Roeder F, Timke C, Oertel S, Hensley FW, Bischof M, Muenter MW, Weitz J, Buchler MW, Lehner B, Debus J, Krempien R.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1154-60. doi: 10.1016/j.ijrobp.2009.03.067. Epub 2009 Aug 3.

PMID:
19647952
22.

[The role of radiation therapy in treatment of pancreatic cancer from the viewpoint of radio-oncologists].

Timke C, Debus JP.

Radiologe. 2009 Feb;49(2):149-53. doi: 10.1007/s00117-008-1758-y. Review. German.

PMID:
19156394
23.

Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma.

Funk A, Hensley F, Krempien R, Neuhof D, Van Kampen M, Treiber M, Roeder F, Timke C, Herfarth K, Helmbold P, Debus J, Bischof M.

Eur J Dermatol. 2008 May-Jun;18(3):308-12. doi: 10.1684/ejd.2008.0394. Epub 2008 May 13.

PMID:
18474461
24.

Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.

Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.

Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893.

25.

Patterns of failure and local control after intraoperative electron boost radiotherapy to the presacral space in combination with total mesorectal excision in patients with locally advanced rectal cancer.

Roeder F, Treiber M, Oertel S, Dinkel J, Timke C, Funk A, Garcia-Huttenlocher H, Bischof M, Weitz J, Harms W, Hensley FW, Buchler MW, Debus J, Krempien R.

Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1381-8. Epub 2007 Jan 31.

PMID:
17275208
26.

Long-term results of intraoperative presacral electron boost radiotherapy (IOERT) in combination with total mesorectal excision (TME) and chemoradiation in patients with locally advanced rectal cancer.

Krempien R, Roeder F, Oertel S, Roebel M, Weitz J, Hensley FW, Timke C, Funk A, Bischof M, Zabel-Du Bois A, Niethammer AG, Eble MJ, Buchler MW, Treiber M, Debus J.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1143-51. Epub 2006 Sep 18.

PMID:
16979835
27.

Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma.

Krempien R, Roeder F, Oertel S, Weitz J, Hensley FW, Timke C, Funk A, Lindel K, Harms W, Buchler MW, Debus J, Treiber M.

Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):773-9. Epub 2006 May 6.

PMID:
16682152
28.

Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518).

Jensen AD, Münter MW, Bischoff H, Haselmann R, Timke C, Krempien R, Sterzing F, Nill S, Heeger S, Hoess A, Haberkorn U, Huber PE, Steins M, Thomas M, Debus J, Herfarth KK.

BMC Cancer. 2006 May 8;6:122.

29.

Intraoperative electron boost radiation followed by moderate doses of external beam radiotherapy in limb-sparing treatment of patients with extremity soft-tissue sarcoma.

Oertel S, Treiber M, Zahlten-Hinguranage A, Eichin S, Roeder F, Funk A, Hensley FW, Timke C, Niethammer AG, Huber PE, Weitz J, Eble MJ, Buchler MW, Bernd L, Debus J, Krempien RC.

Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1416-23. Epub 2006 Jan 18.

PMID:
16413697
30.

Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

Krempien R, Muenter MW, Huber PE, Nill S, Friess H, Timke C, Didinger B, Buechler P, Heeger S, Herfarth KK, Abdollahi A, Buchler MW, Debus J.

BMC Cancer. 2005 Oct 11;5:131.

31.

Interferon alpha 2b treatment in an eleven-year-old boy with disseminated lymphangiomatosis.

Timke C, Krause MF, Oppermann HC, Leuschner I, Claviez A.

Pediatr Blood Cancer. 2007 Jan;48(1):108-11.

PMID:
16007599
32.

[Primary bilateral renal Burkitt lymphoma in childhood].

Order BM, Timke C, Oppermann HC.

Rofo. 2004 Aug;176(8):1175-7. German. No abstract available.

PMID:
15346294
33.

Isolation, long-term culture, and characterization of rat pancreatic fibroblastoid/stellate cells.

Kruse ML, Hildebrand PB, Timke C, Fölsch UR, Schäfer H, Schmidt WE.

Pancreas. 2001 Jul;23(1):49-54.

PMID:
11451147
34.

TGFbeta1 autocrine growth control in isolated pancreatic fibroblastoid cells/stellate cells in vitro.

Kruse ML, Hildebrand PB, Timke C, Fölsch UR, Schmidt WE.

Regul Pept. 2000 Jun 30;90(1-3):47-52.

PMID:
10828492

Supplemental Content

Support Center